不适合移植的大 B 细胞淋巴瘤二线使用 axicabtagene ciloleucel：ALYCANTE 最终分析
Second-line axicabtagene ciloleucel in large B-cell lymphoma ineligible for transplantation: ALYCANTE final analysis.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
弥漫性大 B 细胞淋巴瘤的治疗格局演变：挑战与愿景
英文原题：Evolving therapeutic landscape of diffuse large B-cell lymphoma: challenges and aspirations.
查看英文原题
Evolving therapeutic landscape of diffuse large B-cell lymphoma: challenges and aspirations.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
弥漫性大B细胞淋巴瘤（DLBCL）是非霍奇金淋巴瘤最常见的亚型，包含一组具有独特分子和临床病理特征的异质性疾病实体。过去十年间，对DLBCL分子图景的认识显著提高，突出了具有靶向治疗意义的独特基因组亚型。与此同时，多种新的治疗模式近期已在一线和复发 settings 中获得批准，结束了过去十年困扰该领域的阴性临床试验匮乏局面。尽管如此，在真实世界环境中，药物可及性、报销政策、医生和患者偏好，以及关于治疗选择最佳排序的问题，在日常肿瘤学实践中仍构成困难和挑战。在此，我们综述DLBCL治疗武器库的最新进展，并讨论对实践格局的影响，特别侧重于新加坡医疗体系的背景。
展开英文摘要原文
Diffuse large B-cell lymphoma (DLBCL) represents the commonest subtype of non-Hodgkin lymphoma and encompasses a group of diverse disease entities, each harboring unique molecular and clinico-pathological features. The understanding of the molecular landscape of DLBCL has improved significantly over the past decade, highlighting unique genomic subtypes with implications on targeted therapy.
At the same time, several new treatment modalities have been recently approved both in the frontline and relapsed settings, ending a dearth of negative clinical trials that plagued the past decade. Despite that, in the real-world setting, issues like drug accessibility, reimbursement policies, physician and patient preference, as well as questions regarding optimal sequencing of treatment options present difficulties and challenges in day-to-day oncology practice.
Here, we review the recent advances in the therapeutic armamentarium of DLBCL and discuss implications on the practice landscape, with a particular emphasis on the context of the healthcare system in Singapore.
论文信息
- 作者
- Chan JY、Somasundaram N、Grigoropoulos N、Lim F、Poon ML、Jeyasekharan A、Yeoh KW、Tan D
- 第一作者单位
- Division of Medical Oncology, National Cancer Centre Singapore, 30 Hospital Blvd, Singapore, 168583, Singapore. jason.chan.y.s@singhealth.com.sg.Singapore
- 通讯作者单位
- Division of Medical Oncology, National Cancer Centre Singapore, 30 Hospital Blvd, Singapore, 168583, Singapore. lim.soon.thye@singhealth.com.sg.Singapore
- 文献类型
- 综述
- 期刊
- Discover oncology2023 Jul 19
- 原文标识
- PubMed 37466782 · DOI 10.1007/s12672-023-00754-8
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →